Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma

CYTOTHERAPY

卷 25, 期 2, 页码 185-191

ELSEVIER SCI LTD

chimeric antigen receptor T-cell therapy; autologous transplantation; transformed lymphoma; refractory/relapsed aggressive B-cell; lymphoma

Cell & Tissue Engineering Biotechnology & Applied Microbiology Cell Biology Hematology Medicine, Research & Experimental